Background: Diabetes mellitus, largely type 2, affects nearly 10% of the global adult population according to the World Health Organization. Diabetes is an independent risk factor for atherosclerotic cardiovascular diseases, including coronary artery disease. Diabetes patients experience a two to three-fold increased incidence of coronary artery disease, despite improved metabolic control and management of other cardiovascular risk factors. Discussion: Platelet abnormalities and activation as well as reduced antiplatelet drug responsiveness characterise diabetes mellitus. Mechanisms linking diabetes to platelet and vascular abnormalities, atherogenesis and atherosclerotic cardiovascular disease are still only partially known, highlighting the unique complexity of the pro-atherogenic clinical scenario and its treatment. Consistently, a higher residual cardiovascular risk characterises patients with diabetes compared with those without, in spite of improved antiplatelet and antithrombotic treatment combinations. Randomised clinical trials aimed at optimising antiplatelet treatment specifically in patients with diabetes are lacking, both in acute and chronic coronary artery disease settings. Thus, patients with diabetes are treated with regimens validated in studies including only variable proportions of diabetes patients. Myocardial revascularisation appears to confer a comparable relative benefit between diabetes patients and patients without diabetes, and generally coronary artery bypass grafting has a better outcome in diabetes mellitus versus peripheral coronary intervention. New glucoselowering drugs have been shown to reduce the incidence of major cardiovascular events in secondary prevention. Type 1 diabetes mellitus remains less explored than type 2 in this context. Conclusion: Diabetes-tailored antithrombotic strategies in acute and chronic coronary artery disease remain an unmet clinical need, requiring ad-hoc trials and precision pharmacological strategies.
Introduction
Diabetes mellitus (DM) is the most common form of hyperglycaemia. While type 1 diabetes mellitus (T1DM) is characterised by a complete or nearly complete absence of insulin, the most common type 2 diabetes mellitus (T2DM) (approximately equal to 90% of all cases) is characterised by insulin resistance and a progressive inability of pancreatic b-cells to synthesise and release insulin. 1 A higher cardiovascular risk in DM has emerged since the 1970s when a two to four-fold increase in symptomatic atherosclerotic cardiovascular disease (ASCVD) in T2DM patients versus non-DM patients was reported. 2 The Emerging Risk Factors Collaboration reported a doubled risk of coronary artery disease (CAD) (hazard ratio (HR) 2.00, 95% confidence interval (CI) 1.83-2. 19 ), largely in T2DM, accounting for traditional (age, smoking, body mass index, blood pressure) and emerging (inflammation) risk factors. 3 An ASCVD risk increased up to four times has recently been demonstrated also in T1DM, influenced not only by glucose control (e.g. glycated haemoglobin) but also by albuminuria, disease duration, blood pressure and low-density lipoprotein cholesterol. 4 These findings in T1DM and T2DM suggest a role of hyperglycaemia in ASCVD, further supported by the observation that the cardiovascular risk increase parallels the levels of glycated haemoglobin also in pre-diabetes ranges, as in impaired glucose tolerance. 3 While data have consistently shown an association of T1DM and T2DM with increased ASCVD including CAD, the relationship between the control of hyperglycaemia and reduction of ASCVD is definitely established in T1DM 5 but not in T2DM. 6 Although cardiovascular disease and death have been declining in T1DM, T2DM and in non-DM patients over the past 20 years, 7 the residual absolute risk of cardiovascular disease and mortality nonetheless remains higher in both DM types. 3, 7 Therefore, antiplatelet therapies and myocardial revascularisation (MR) when indicated, remain of outmost importance in DM.
Platelet activation
Accelerated atherosclerosis in DM is multifactorial, involving endothelial dysfunction, platelet activation, thrombin generation and inflammation (Figure 1(a) ). Platelet activation can be detected already in impaired glucose tolerance and newly diagnosed T2DM, 8, 9 also in animal models. 10 Altered platelet generation reported in DM appears to be characterised by megakaryocyte aneuploidy, 11 increased platelet mass, 12 altered platelet count versus volume ratio 8, 12 and increased young and hyperreactive platelets. 13 Consistently, animal models have shown that the glucose transporter-3 on megakaryocytes and platelets contributes to thrombopoiesis, platelet count and activation, 14 and mice with diabetes exhibit high reticulated platelets. 13 In vivo platelet activation is detectable in T1DM and T2DM compared with non-DM individuals, as reflected by the high excretion of metabolites of platelet-derived thromboxane (TX)A 2 15,16 that promotes aggregation. Established DM is characterised by several platelet abnormalities (Figure 1(b) , Supplementary Files) also without symptomatic ASCVD, increased in vitro thrombin generation, 17 thicker clots and reduced fibrinolysis in vitro. 18 Platelet activation in DM may be related to postprandial hyperglycaemia, hyperinsulinemia, inflammation, obesity and endothelial dysfunction (reviewed in Cosentino et al.) . 3 Persistent platelet activation and hyperresponsiveness are known to contribute to atherosclerosis development and complications. 19 Suboptimal platelet inhibition characterises T2DM patients on antiplatelet drugs, probably through different mechanisms ( Figure 2 ). A reduced inhibition of platelet-derived TXA 2 may occur in about 30% of T2DM patients on standard once-daily, low-dose aspirin, rescued by a twice-daily regimen rather than by increasing the once-daily dose. 20, 21 The clopidogrel active metabolite concentration is lower in DM versus non-DM patients. 22, 23 Consistently, poor responsiveness appears to be more frequent in clopidogrel-treated T2DM versus non-DM patients and in clopidogreltreated versus prasugrel-treated T2DM patients. 22 Thus, DM seems to combine suboptimal pharmacological responsiveness with persistent in vivo platelet activation.
Cardiovascular prevention post-acute coronary syndrome
The best current evidence for treating DM patients post-acute coronary syndrome (ACS) as well as with chronic coronary syndromes derives from subgroup investigation (i.e. interaction analysis) of randomised clinical trials (RCTs) largely including non-DM patients, which has intrinsic methodological limitations. 24 RCTs are designed and powered to determine the main effect of a treatment: the sample size required to demonstrate an interaction effect of a magnitude similar to that of the main effect is at least four times. 25 Moreover, as the effect of antiplatelet therapy may depend on the levels of hyperglycaemia, differences in glycaemic control across RCTs may influence the efficacy of the antiplatelet intervention. 26 Low-dose aspirin is recommended together with a P2Y 12 receptor blocker (dual antiplatelet therapy; DAPT) in secondary prevention post-ACS and/or post-percutaneous coronary intervention (PCI) 27 also in DM (Table 1) . Aspirin permanently inhibits cyclooxygenase-1 dependent TXA 2 biosynthesis from platelets. 28 The superior efficacy of inhibiting two platelet pathways (cyclooxygenase-1 and P2Y 12 receptor) versus cyclooxygenase-1 alone was first demonstrated in the Clopidogrel in Unstable Angina to Prevent Recurrent Event (CURE) trial in which 12,562 aspirin-treated ACS patients were randomly allocated to clopidogrel or placebo. 29 Aspirin and clopidogrel reduced by 20% major adverse cardiovascular events (MACE: cardiovascular death, non-fatal MI and nonfatal stroke) versus aspirin and placebo, similarly in patients with and without DM ( Table 2 ). The high interindividual variability of P2Y 12 inhibition exerted by clopidogrel, due to its complex pharmacokinetics, 28 prompted the development of prasugrel, an irreversible inhibitor with improved pharmacokinetics. 28 In the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction-38 (TRITON-TIMI-38), 13,608 PCI-candidate, aspirintreated ACS patients (3146 with DM) were randomly allocated to either prasugrel or clopidogrel. 30 Prasugrel showed a trend towards higher proportional and absolute benefit in the DM versus non-DM cohorts (HR 0.70 versus 0.86, respectively, P interaction ¼ 0.09, Table 2 ). 30 With the known limitations of a subgroup analysis, the poor responsiveness to clopidogrel especially in DM 22 may in part explain these data. In the PLATelet inhibition and patient Outcomes (PLATO) trial, 18,624 aspirin-treated ACS patients were randomly allocated to ticagrelor or clopidogrel. As compared with clopidogrel, DAPT with ticagrelor resulted in a similar relative risk reduction (RRR) of MACE in DM and non-DM cohorts (12% and 17%, respectively) ( Table 2 ). 31 In the recent ISAR-REACT 5 trial, 4018 aspirin-treated ACS patients were randomly allocated to prasugrel or ticagrelor. 32 Table 1 . Guidelines on the use of antithrombotic drugs in secondary prevention in patients with diabetes mellitus.
Organisation (year) Recommendation
Class (level of evidence) ADA (2019) 60 Use aspirin therapy (75-162 mg/day) as a secondary prevention strategy in those with diabetes and a history of atherosclerotic cardiovascular disease A ADA (2019) 60 Dual antiplatelet therapy (with low-dose aspirin and a P2Y 12 inhibitor) is reasonable for a year after an acute coronary syndrome and may have benefits beyond this period A B ESC (2019) 3 Aspirin at a dose of 75-160 mg/day is recommended as secondary prevention in DM Treatment with a P2Y 12 receptor blocker, ticagrelor or prasugrel, is recommended in patients with DM and ACS for one year with aspirin, and in those who undergo PCI or CABG 3 Prolongation of DAPT beyond 12 months should be considered, for up to 3 years, in patients with DM who have tolerated DAPT without major bleeding complications The addition of a second antithrombotic drug on top of aspirin for long-term secondary prevention should be considered in patients without high bleeding risk
Analysis of study data suggests that in patients treated for one year with DAPT without significant bleeding or ischaemic events, the benefit/risk ratio with prolonged DAPT may be favourable for those with a high DAPT score (!2) because prolonged DAPT reduces net (ischaemic plus bleeding) events when compared with non-prolonged DAPT
No class of recommendation associated
ACC: American College of Cardiology; ACS: acute coronary syndrome; ADA: American Diabetes Association; AHA: American Heart Association; DAPT: dual antiplatelet therapy; DM: diabetes mellitus; ESC: European Society of Cardiology; MI: myocardial infarction. DAPT score includes DM with a score of þ1.
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Protein receptor glycation Activated platelets Figure 2 . Potential mechanisms that may affect antiplatelet drug responsiveness in diabetes mellitus (DM). Several mechanisms, selectively operating in DM, may affect the pharmacodynamics and pharmacokinetics of antiplatelet drugs in a specific or non-specific (i.e. protein glycation, high baseline platelet activation) manner. The figure depicts the mechanisms that may interfere with each oral antiplatelet drug, hampering its inhibitory capacity. and higher drug discontinuation rate compared with prasugrel ( Table 2) . DM patients were relatively few (n ¼ 892) and the absolute number of MACE was very low (51 versus 55 in ticagrelor and prasugrel, respectively). In all these RCTs, DM patients constantly showed a higher residual absolute incidence of MACE as compared with non-DM patients, irrespective of the randomised treatment and study period ( Table 2) , consistent with data of high platelet activation despite antiplatelet treatment. Moreover, the highest MACE rate is observed in insulin-treated DM patients (Tables 2 and 3 ). 30, 31 With the possible exception of prasugrel, HRs showed no major differences in the relative extent of benefit in DM versus non-DM patients in the CURE and PLATO studies, which would correspond to a higher absolute benefit in DM patients given their higher absolute risk ( Table 2) . Despite the clinical superiority of blocking two platelet pathways with DAPT, the GLOBAL LEADERS trial tested the superiority of blocking only P2Y 12 with 24-month ticagrelor post-ACS versus standard 12month DAPT, followed by 12-month aspirin monotherapy, on all-cause mortality or non-fatal Q-wave MI (primary endpoint) and major bleeding (secondary endpoint). 33 The rationale relied on some conflicting in vitro studies hypothesising a similar platelet inhibition by the clopidogrel active metabolite with or without aspirin. 34, 35 The uncertain preclinical data can explain the negative results of the trial: ticagrelor monotherapy had no superior efficacy or safety versus standard DAPT plus aspirin monotherapy in the overall and DM (25% of participants) cohorts. 33 Consistently, ticagrelor monotherapy has no approval post-ACS. The Testing Responsiveness To Platelet Inhibition On Chronic Antiplatelet Treatment For ACS (TROPICAL-ACS) trial recently tested the non-inferiority of 'de-escalating' P2Y 12 inhibition from prasugrel to clopidogrel during the first 2 weeks on DAPT. ACS patients undergoing PCI were randomly allocated to standard DAPT with prasugrel or 'de-escalation', which comprised continuing prasugrel or switching to clopidogrel based on platelet function testing. 36 The limitations of that trial include the wide non-inferiority margin (30%), relatively low power (80%), a primary endpoint combining both efficacy (MACE) and safety (moderate and major bleeding) outcomes, the use of platelet function testing which failed validation in a prospective, superiority RCT. 37 Therefore, with a relatively small sample size (n ¼ 2610) the TROPICAL showed a non-inferiority of de-escalated versus traditional DAPT (HR 0.81, 95% CI 0.62-1.06). Notably, in the small DM subgroup (n ¼ 527), the result (HR 1.17, 95% CI 0.71-1.93) cannot exclude a harm of the de-escalation, consistently with the superiority of DAPT demonstrated by TRITON-TIMI-38, especially in DM. The 2019 European Society of Cardiology (ESC) guidelines recommend 12-month DAPT post ACS in DM patients (Table 1) , with no de-escalation or platelet testing. 3 Given the high residual thrombotic risk even with optimised DAPT, compliance is crucial in DM patients, because large observational studies including DM patients showed that interrupting either the P2Y 12 inhibitor or aspirin from DAPT, particularly in the first 6 months, is associated with significantly worse outcomes. 38, 39 A large observational study, 40 a metaanalysis of RCTs that enrolled between 25% and 38% of DM patients, 41 and a recent trial in DM, 32 showed that 25-35% of patients prematurely interrupt ticagrelor. Dyspnoea, a ticagrelor-specific adverse effect, accounts for approximately equal to 50% of discontinuation (HR 6.40, 95% CI 5.39-7.41 versus comparators in RCT). 41 Thus, the possibility of low adherence to DAPT due to dyspnoea should be considered in DM patients before prescribing ticagrelor, because antiplatelet drug discontinuation could be particularly dangerous in DM given the high residual cardiovascular risk.
The optimal antiplatelet treatment post-coronary artery bypass grafting (CABG) in DM patients also relies on studies including DM and non-DM patients, and depends on whether CABG is performed in ACS or stable CAD. 3, 42 The 2019 ESC guidelines recommend DAPT after CABG post-ACS for 12 months. 3 
Revascularisation strategies
MR is the treatment of choice for symptomatic patients with significant CAD. 42 In asymptomatic patients, optimal medical therapy should generally be the first-line treatment, with MR being considered when large areas of ischaemia or significant left main or proximal left anterior descending stenoses are present. 42 Surgical, i.e. CABG, rather than percutaneous, i.e. coronary angioplasty (PCI), MR can be selected based on the number, site and complexity of significant coronary lesions, and on the clinical context, i.e. stable CAD or ACS (at least with regard to the culprit lesion). The ability to achieve complete revascularisation, which critically affects the symptomatic and prognostic benefit of MR, 42 should be considered when choosing the strategy. The recommendations on MR for the general cardiovascular population also apply to DM. 3, 42 No interaction has been shown between DM and the benefit of MR. 42 Given the higher baseline risk of MACE, absolute risk reduction with MR is larger in DM versus non-DM patients (3.7% versus 0.1%; P interaction ¼ 0.02). 42 The adverse prognosis of incomplete MR in non-DM has also been shown for DM patients. 3, 42 No clear interaction between insulin versus non-insulin treatment has been reported CABG: coronary artery bypass grafting; CAD: coronary artery disease; DM: diabetes mellitus; HR: hazard ratio; LD: loading dose; MACE: major arterial cardiovascular events (cardiovascular death, myocardial infarction, stroke); MD: maintaining dose; PCI: percutaneous coronary intervention; PTCA: percutaneous transluminal coronary angioplasty; TIMI: thrombolysis in myocardial infarction.
HRs are always indicated with (95% confidence interval). Studies are listed according to the year of publication and order of citation in the text.
regarding the relative effect of CABG and PCI on the incidence of MACE, 42 yet insulin-treated patients display higher absolute MACE rates. 42 However, the higher prevalence of left main and multivessel and/or diffuse disease, and the increased risk of restenosis associated with DM, 42, 43 may influence the mode of MR. Current recommendations on the choice between CABG and/or PCI are summarised in Supplementary  Table 1 . Several RCTs have compared CABG and PCI in DM. 3, 42 In general, CABG was associated with better outcomes (versus first-generation drug-eluting stents (DES) or bare metal stents), in terms of MACE, death or MI. 3, 42 Conversely, the stroke rate was generally lower with PCI. 42, 44 Repeated MR was consistently lower with CABG, especially at low ( 22) or intermediate (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) SYNTAX scores, an indicator of the anatomical complexity of CAD. 42, 45 In a metaanalysis including 3052 DM patients, PCI with firstgeneration DES was confirmed to be inferior to CABG on death (14% versus 9.7%; risk ratio (RR) 1.51, 95% CI 1.09-2.10) and MI (10.3% versus 5.9%; RR 1.44, 95% CI 0.79-2.6), and superior on the occurrence of stroke (2.3% versus 3.8%; RR 0.59, 95% CI 0.39-0.90). 46 Initial data suggesting that the benefits with CABG over PCI might be lost with new-generation DES, better performing in terms of the incidence of subsequent thrombosis and restenosis, have not been confirmed. 42 Nonetheless, the implantation of a newgeneration DES is currently recommended irrespective of DM. 3, 42 Procedural aspects of PCI, including preference for the radial approach, single-stent (main vessel only) technique in bifurcation lesions, intracoronary imaging to optimise stent implantation, especially in the left main, and recanalisation of chronic total occlusion in the presence of refractory angina or a large area of ischaemia in the territory of the occluded vessel, are also the same, irrespective of DM. 42 The optimal surgical revascularisation strategy in DM patients is incompletely defined. Whereas bilateral internal mammary artery CABG appears the best choice due to superior patency and survival when grafted to the left anterior descending artery, a mortality benefit compared with single internal mammary artery CABG has not been convincingly proved. 3 Based on current data, either saphenous veins or the radial artery may be considered in addition to single internal mammary artery CABG, although the latter may be preferable due to higher long-term patency. 3
Long-term antithrombotic treatment in chronic coronary syndromes
Low-dose aspirin is recommended long term for stable, post-MI patients, including DM (Table 1) , based on a large meta-analysis of 20,006 post-MI patients,
showing a 25% RRR of MACE without heterogeneity between DM and non-DM. 47 The possible benefit of DAPT beyond 12 months after ACS and/or PCI has been investigated in several RCTs in patients with and without DM. The Dual AntiPlatelet Therapy (DAPT) trial compared 12 versus 30 months of DAPT (aspirin plus clopidogrel or prasugrel) in 9961 patients with DES. Overall, 30month prolongation was associated with a 29% RRR of MACE and a 61% relative increase in severe to moderate but not in fatal or intracranial bleeding ( Table 3 ). 48 However, there was an apparent reduced efficacy of prolonged DAPT in the DM versus non-DM group (P interaction ¼ 0.01, Table 3 ). As two-thirds of the patients were on clopidogrel, this apparent lower benefit in DM may reflect the reduced responsiveness in the large fraction of clopidogrel-treated DM patients. 22 The PEGASUS-TIMI-54 trial compared two doses of ticagrelor (90 or 60 mg) to placebo in aspirin-treated patients with at least another cardiovascular risk factor, including DM, one to 3 years post-MI. 49 As compared with placebo, ticagrelor 60 mg was associated with a similar HR for MACE in the non-DM and DM groups (0.84, 95% CI 0.72-0.98 and 0.83, 95% CI 0.69-1.04, respectively), and with a 2.3-fold increase in thrombolysis in myocardial infarction (TIMI) major but not in fatal or intracranial bleeding, regardless of DM, over 33 months of follow-up ( Table 3 ). The absolute benefit of combined ticagrelor arms versus placebo was 1.1% and 1.5% in non-DM versus DM patients. The benefit/risk balance of this combination beyond 3 years remains unknown.
The Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial tested a different antithrombotic strategy, targeting platelets (cyclooxygenase-1) and coagulation (factor Xa). Highrisk patients with chronic ASCVD, mostly stable CAD, were randomly allocated to low-dose aspirin (reference therapy), rivaroxaban 5 mg twice daily or the combination of aspirin and low-dose rivaroxaban (2.5 mg twice daily). 50 In 24,824 patients with stable CAD, aspirin plus rivaroxaban determined a 26% RRR of MACE and 66% relative increase in major but not in fatal or intracranial bleeding compared with aspirin alone (Table 3 ). 51 The proportional benefit and risk of the aspirin/rivaroxaban combination was similar regardless of DM (38% of participants) ( Table 3) .
The recent 2019 ESC guidelines recommend continuing DAPT beyond 12 months post-ACS and have included the reduced dose ticagrelor or rivaroxaban 2.5 mg twice daily in post-MI patients at long term (Table 1) . 3 Consistently, the PARIS registry showed that DAPT is prescribed for a significantly longer time in DM versus non-DM patients post-DES. 52 Patients without previous MI but with stable angina (SA) and/or angiographically confirmed CAD are a special category of patients at high risk of MACE, even more in the presence of DM. The Swedish Angina Pectoris Aspirin Group (SAPAT) trial enrolled 2035 SA patients and showed a 34% RRR of aspirin versus placebo of MI and sudden death over 55 months of follow-up. Only 7% of patients had DM (Table 3 ). 53 In the recent Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study (THEMIS) trial, DM patients with angiographically confirmed CAD (including SA) and no previous MI or stroke, on low-dose aspirin were randomly allocated to placebo or ticagrelor 60 mg. 32 Ticagrelor was associated with a modest MACE reduction (HR 0.90, 95% CI 0.81-0.99), a 2.32-fold increase in TIMI major and 71% significant relative increase in intracranial bleeding (Table  3) . Moreover, 34.5% of patients permanently discontinued ticagrelor during the trial. Therefore, DAPT with ticagrelor did not show a net benefit in these high-risk DM patients. Moreover, the relative benefit observed for ticagrelor was lower than predicted based on the PEGASUS trial (10% observed versus 16% predicted). Therefore, the benefits of ticagrelor may be reduced by DM status in the chronic setting.
New glucose-lowering drugs in secondary cardiovascular prevention
Recent guidelines suggest two new classes of glucoselowering medications, glucagon-like peptide-1 (GLP-1) receptor agonists (incretins; GLP-1RAs) and sodiumglucose cotransporter 2 (SGLT-2) inhibitors (gliflozins; SGLT-2is), in patients with T2DM and established ASCVD. 3, 54 Although current knowledge would not indicate that the cardiovascular protective effects of these medications are directly mediated by mechanisms involving haemostasis, they should be preferred to other glucose-lowering medications given their safety and efficacy demonstrated in multiple cardiovascular outcome trials (CVOTs), as detailed in the Supplementary Files  and Supplementary Table 2 . Most CVOTs included patients both with and without ASCVD and the treatment effect in patients with ASCVD is reported as subgroup analysis. A recent meta-analysis confirmed that both drug classes reduce MACE specifically in patients with established ASCVD: HR 0.87 (95% CI 0.82-0.92) for GLP-1RAs and 0.86 (95% CI 0.80-0.93) for SGLT-2is. 55 Other meta-analyses confirmed that GLP-1RAs effectively modulate ASCVD risk, 56 while SGLT-2is mainly improve heart failure and renal outcomes. 57, 58 GLP-1RAs and SGLT2-is have also been investigated in T1DM patients on top of insulin for intermediate glucometabolic outcomes, but no CVOTs are currently available.
Conclusions
Research in recent decades has increased our understanding of the links between DM and haemostatic abnormalities, atherogenesis and acute and chronic coronary syndromes, highlighting the unique complexity of pro-thrombotic mechanisms and the reduced antiplatelet drug responsiveness in DM, mostly in T2DM. Despite the evidence of a consistent high residual cardiovascular risk in patients with DM in secondary prevention, RCTs specifically conducted in DM patients aimed at identifying the optimal, possibly intensified antiplatelet strategy are lacking in both the acute and chronic setting. The ongoing ANDAMAN (Aspirin Twice a Day in Patients With Diabetes and Acute Coronary Syndrome) RCT is testing the efficacy and safety of once versus twice-daily low-dose aspirin in patients with DM and ACS. 59 Notably, the higher residual risk in individuals with DM translates into a larger absolute treatment effect in these patients in some trials, although the interaction analyses by the presence of DM conducted in the RCTs would suggest a similar relative treatment effect of antithrombotic therapies, mostly antiplatelets. Moreover, in spite of evidence that T1DM and pre-diabetes states are associated with increased ASCVD, more data are needed in secondary prevention in these two populations, largely underrepresented or even absent in large trials. Hence, DM-tailored, intensified antithrombotic strategies remain an unmet clinical need.
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